Albemarle's stock surged 5.20% during intraday trading on Friday, reflecting strong positive sentiment from investors.
The move follows a series of bullish analyst actions, including Morgan Stanley raising its price target on the stock to $170 from $147 while maintaining an Equalweight rating, and Citigroup adjusting its target to $190 from $180. These revisions signal growing confidence in the company's financial prospects.
Further optimism stems from the company's strategic decision to idle its Kemerton lithium hydroxide plant, which is expected to improve adjusted EBITDA from the second quarter of 2026 while maintaining its 2026 volume guidance. This focus on operational efficiency and cost savings is being viewed as a potential game-changer for the lithium producer.